1-((R)-2-Hydroxymethyl-4-[2-trifluoromethyl-4-(2-trifluoromethyl-pyrimidin-5-yl)-thiazol-5-yl]-piperazin-1-yl)-2-(3-methyl-pyrazol-1-yl)-ethanone

ID: ALA5278881

Chembl Id: CHEMBL5278881

Max Phase: Preclinical

Molecular Formula: C20H19F6N7O2S

Molecular Weight: 535.47

Associated Items:

Names and Identifiers

Canonical SMILES:  Cc1ccn(CC(=O)N2CCN(c3sc(C(F)(F)F)nc3-c3cnc(C(F)(F)F)nc3)C[C@@H]2CO)n1

Standard InChI:  InChI=1S/C20H19F6N7O2S/c1-11-2-3-32(30-11)9-14(35)33-5-4-31(8-13(33)10-34)16-15(29-18(36-16)20(24,25)26)12-6-27-17(28-7-12)19(21,22)23/h2-3,6-7,13,34H,4-5,8-10H2,1H3/t13-/m1/s1

Standard InChI Key:  GQQMDOGXIJRPDK-CYBMUJFWSA-N

Alternative Forms

  1. Parent:

    ALA5278881

    ---

Associated Targets(Human)

CXCR3 Tchem C-X-C chemokine receptor type 3 (2736 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
KCNH2 Tclin HERG (29587 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
CYP2D6 Tclin Cytochrome P450 2D6 (33882 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
CYP3A4 Tclin Cytochrome P450 3A4 (53859 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 535.47Molecular Weight (Monoisotopic): 535.1225AlogP: 2.85#Rotatable Bonds: 5
Polar Surface Area: 100.27Molecular Species: NEUTRALHBA: 9HBD: 1
#RO5 Violations: 1HBA (Lipinski): 9HBD (Lipinski): 1#RO5 Violations (Lipinski): 1
CX Acidic pKa: CX Basic pKa: 3.31CX LogP: 2.46CX LogD: 2.46
Aromatic Rings: 3Heavy Atoms: 36QED Weighted: 0.50Np Likeness Score: -1.36

References

1. Meyer EA, Äänismaa P, Ertel EA, Hühn E, Strasser DS, Rey M, Murphy MJ, Martinic MM, Pouzol L, Froidevaux S, Keller MP, Caroff E..  (2023)  Discovery of Clinical Candidate ACT-777991, a Potent CXCR3 Antagonist for Antigen-Driven and Inflammatory Pathologies.,  66  (6): [PMID:36883854] [10.1021/acs.jmedchem.3c00074]

Source